MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Ovid therapeutics Inc

Closed

SectorHealthcare

0.3 -9.09

Overview

Share price change

24h

Current

Min

0.3

Max

0.33

Key metrics

By Trading Economics

Income

4.8M

-9.3M

Sales

-97K

76K

EPS

-0.13

Profit margin

-12,175

Employees

23

EBITDA

2.5M

-11M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+855.88% upside

Market Stats

By TradingEconomics

Market Cap

-12M

25M

Previous open

9.39

Previous close

0.3

News Sentiment

By Acuity

50%

50%

180 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Ovid therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 cze 2024, 13:34 UTC

Major Market Movers

Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback

Peer Comparison

Price change

Ovid therapeutics Inc Forecast

Price Target

By TipRanks

855.88% upside

12 Months Forecast

Average 3.25 USD  855.88%

High 4 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forOvid therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

0.3 / 0.4257Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

180 / 386 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.